Lintuzumab
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice[1].
Product Specifications
CAS Number
166089-32-3
Product Name Alternative
SGN-33; HuM-195
UNSPSC
12352203
Target
Radionuclide-Drug Conjugates (RDCs) ; Transmembrane Glycoprotein
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/lintuzumab.html
Purity
98.09
Solubility
H2O
Smiles
[Lintuzumab]
Molecular Weight
(145.24 kDa)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Isoform
RDC Antibody
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Prostate Specific Antigen (PSA) (KLK3/2871R), CF568 conjugate, 0.1mg/mL
![Tide Quencher™ 7.1 CPG [TQ7.1 CPG] *500 Å*](https://cdn.genprice.uk/products/271/11579490/imageurl/2116-aat.webp)
Recombinant Human Cadherin-17/CDH17 Protein (His Tag)